Desflurane volatile liquid

Land: Storbritannia

Språk: engelsk

Kilde: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktiv ingrediens:

Desflurane

Tilgjengelig fra:

Baxter Healthcare Ltd

ATC-kode:

N01AB07

INN (International Name):

Desflurane

Dosering :

1ml/1ml

Legemiddelform:

Inhalation vapour

Administreringsrute:

Inhalation

Klasse:

No Controlled Drug Status

Resept typen:

Valid as a prescribable product

Produkt oppsummering:

BNF: 15010200; GTIN: 00085412586595

Preparatomtale

OBJECT 1
DESFLURANE 100% V/V INHALATION VAPOUR, LIQUID
Summary of Product Characteristics Updated 05-Mar-2018 | Baxter
Healthcare Ltd
1. Name of the medicinal product
Desflurane 100% v/v Inhalation vapour, liquid
2. Qualitative and quantitative composition
Desflurane, supplied as pure drug substance.
3. Pharmaceutical form
Inhalation vapour, liquid
4. Clinical particulars
4.1 Therapeutic indications
Desflurane is indicated as an inhalation agent for induction and/or
maintenance of anaesthesia for
inpatient and outpatient surgery in adults and maintenance of
anaesthesia for inpatient and outpatient
paediatric surgery.
4.2 Posology and method of administration
Method of administration
Desflurane is administered by inhalation.
Desflurane should only be administered by persons trained in the
administration of general anaesthesia
using a vaporizer specifically designed and designated for use with
desflurane.
Premedication
Premedication should be selected according to the needs of the
individual patient taking into account that
salivary secretions are stimulated. The use of anticholinergic drugs
is a matter of choice for the
anaesthetist.
Individualization
The administration of general anaesthesia must be individualized based
on the patient's response.
Effects on Concomitant Therapy
Opioids or benzodiazepines decrease the amount of desflurane required
to produce anaesthesia.
Desflurane decreases the required doses of neuromuscular blocking
agents (see Table 2, section 4.5). If
added relaxation is required, supplemental doses of muscle relaxants
may be used. (See section 4.5)
Dosage
The minimum alveolar concentration (MAC) of desflurane decreases with
increasing patient age. The
dose of desflurane should be adjusted accordingly. The MAC has been
determined as listed in Table 1.
Table 1
MAC for desflurane according to patient age and inhalation mixture
(Mean±SD)
Age
N*
100% Oxygen
N*
60% Nitrous Oxide/40%
Oxygen
2 weeks
6
9.2±0.0
-
-
10 weeks
5
9.4±0.4
-
-
9 months
4
10.0±0.7
5
7.5±0.8
2 years
3
9.1±0.6
-
-
3 years